Literature DB >> 21037328

B-cell-directed therapy for chronic graft-versus-host disease.

Caron A Jacobson, Jerome Ritz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21037328      PMCID： PMC2966901          DOI： 10.3324/haematol.2010.032227

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  21 in total

1.  Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches.

Authors:  Marilyn Thien; Tri Giang Phan; Sandra Gardam; Michelle Amesbury; Antony Basten; Fabienne Mackay; Robert Brink
Journal:  Immunity       Date:  2004-06       Impact factor: 31.745

2.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.

Authors:  David B Miklos; Haesook T Kim; Katherine H Miller; Luxuan Guo; Emmanuel Zorn; Stephanie J Lee; Ephraim P Hochberg; Catherine J Wu; Edwin P Alyea; Corey Cutler; Vincent Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2004-12-21       Impact factor: 22.113

Review 3.  The role of APRIL and BAFF in lymphocyte activation.

Authors:  Pascal Schneider
Journal:  Curr Opin Immunol       Date:  2005-06       Impact factor: 7.486

4.  Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations.

Authors:  Chunyan Zhang; Ivan Todorov; Zhifang Zhang; Yinping Liu; Fouad Kandeel; Stephen Forman; Samuel Strober; Defu Zeng
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

5.  Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease.

Authors:  Marijke R Canninga-van Dijk; Hanneke M van der Straaten; Rob Fijnheer; Cornelus J Sanders; Jan G van den Tweel; Leo F Verdonck
Journal:  Blood       Date:  2004-07-13       Impact factor: 22.113

6.  The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery.

Authors:  Francesca Patriarca; Cristina Skert; Alessandra Sperotto; Francesco Zaja; Edmondo Falleti; Rosalba Mestroni; Francesca Kikic; Elisabetta Calistri; Carla Filì; Antonella Geromin; Michela Cerno; Renato Fanin
Journal:  Exp Hematol       Date:  2006-03       Impact factor: 3.084

7.  High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Nazmim S Bhuiya; Corey S Cutler; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Clin Cancer Res       Date:  2007-10-15       Impact factor: 12.531

8.  Rituximab for steroid-refractory chronic graft-versus-host disease.

Authors:  Corey Cutler; David Miklos; Haesook T Kim; Nathaniel Treister; Sook-Bin Woo; Don Bienfang; Lloyd B Klickstein; Jesse Levin; Katherine Miller; Carol Reynolds; Rebecca Macdonell; Mildred Pasek; Stephanie J Lee; Vincent Ho; Robert Soiffer; Joseph H Antin; Jerome Ritz; Edwin Alyea
Journal:  Blood       Date:  2006-03-21       Impact factor: 22.113

9.  Treatment of refractory chronic GVHD with rituximab: a GITMO study.

Authors:  F Zaja; A Bacigalupo; F Patriarca; M Stanzani; M T Van Lint; C Filì; R Scimè; G Milone; M Falda; C Vener; D Laszlo; P E Alessandrino; F Narni; S Sica; A Olivieri; A Sperotto; A Bosi; F Bonifazi; R Fanin
Journal:  Bone Marrow Transplant       Date:  2007-06-04       Impact factor: 5.483

10.  Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation.

Authors:  Emmanuel Zorn; David B Miklos; Blair H Floyd; Alex Mattes-Ritz; Luxuan Guo; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  J Exp Med       Date:  2004-04-19       Impact factor: 14.307
View more
  3 in total

1.  The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study.

Authors:  Suzanne van Dorp; Henrike Resemann; Liane te Boome; Floor Pietersma; Debbie van Baarle; Frits Gmelig-Meyling; Roel de Weger; Eefke Petersen; Monique Minnema; Henk Lokhorst; Saskia Ebeling; Scott J P Beijn; Edward F Knol; Marijke van Dijk; Ellen Meijer; Jürgen Kuball
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

2.  Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease.

Authors:  Kathy S Wang; Haesook T Kim; Sarah Nikiforow; Alexander T Heubeck; Vincent T Ho; John Koreth; Edwin P Alyea; Philippe Armand; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Corey S Cutler; Jerome Ritz
Journal:  Blood       Date:  2017-11-14       Impact factor: 22.113

Review 3.  Treatment of chronic graft-versus-host disease in 2011.

Authors:  Yoshihiro Inamoto; Mary E D Flowers
Journal:  Curr Opin Hematol       Date:  2011-11       Impact factor: 3.284
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.